Current use of beta-blockers in patients with coronary artery disease
| Autor: | Charlotte Andreasen, Charlotte Andersson |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Symptomatic treatment Disease Coronary Artery Disease 030204 cardiovascular system & hematology law.invention Coronary artery disease 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law medicine Humans In patient 030212 general & internal medicine Myocardial infarction Intensive care medicine Evidence-Based Medicine business.industry Adrenergic beta-Agonists medicine.disease Treatment Outcome Heart failure Practice Guidelines as Topic Observational study Cardiology and Cardiovascular Medicine business |
| Zdroj: | Trends in cardiovascular medicine. 28(6) |
| ISSN: | 1873-2615 |
| Popis: | Beta-blockers have long comprised a cornerstone in the symptomatic treatment of ischemic heart disease and in the secondary prevention of myocardial infarction and heart failure. The majority of studies underlying the evidence of a beneficial effect of beta-blockers on outcomes were conducted more than 25 years ago. In a contemporary era where treatment strategies and secondary prophylactic therapy have undergone several changes, the continued role of beta-blockers in ischemic heart disease has been questioned, especially in the absence of heart failure or a recent myocardial infarction. In summary, few randomized clinical trials are available on the effect of beta-blockers in the reperfusion era, especially on hard endpoints. Likewise, the results of numerous observational studies and meta-analysis are conflicting, emphasizing the need for additional large-scale randomized clinical trials to evaluate the role of beta-blocker therapy in current clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect